Ethinylestradiol/cyproterone versus pioglitazone + flutamide + metformin in adolescent girls with androgen excess.

Trial Profile

Ethinylestradiol/cyproterone versus pioglitazone + flutamide + metformin in adolescent girls with androgen excess.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Flutamide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Ethinylestradiol/cyproterone
  • Indications Hyperandrogenism
  • Focus Pharmacodynamics
  • Acronyms DIO
  • Most Recent Events

    • 18 Jun 2013 Results presented at the 95th Annual Meeting of the Endocrine Society.
    • 30 Jun 2011 New trial record
    • 05 Jun 2011 Results presented at the 93rd Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top